Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Hampshire Health Report.
Press releases published on June 4, 2025
Finish Healing First: Ekol Hospitals Urges Medical Travellers to Stay Until Fully Cleared
GlobeNewswire
·
June 4, 2025
Photo: Ekol Hospitals via FL Communications IZMIR, Türkiye, June 04, 2025 (GLOBE NEWSWIRE) -- As health-travel numbers continue to climb, people are crossing borders for faster appointments, personalised treatment, and more affordable surgical options. Yet …
Highridge Medical Completes the Sale of its Bone Healing Division to Streamline Strategic Focus and Innovation in Spine
GlobeNewswire
·
June 4, 2025
WESTMINSTER, Colo., June 04, 2025 (GLOBE NEWSWIRE) -- Highridge Medical (“Highridge” or the “Company”), one of the world’s largest privately held Spine companies, has completed the sale of EBI, its Bone Healing division, to Avista Healthcare Partners. The …
Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)
GlobeNewswire
·
June 4, 2025
Annamycin delivering better performance 7th line than would be expected even in 2nd line for monotherapy Responders (Stable Disease or Partial Response) after 2 cycles of Annamycin showed improvement in OS and Progression Free Survival (“PFS”) Clinical …
Glucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association’s 85th Scientific Sessions
GlobeNewswire
·
June 4, 2025
Glucotrack to present on next-generation continuous blood glucose monitoring technology in Innovation Hub Poster presentation to highlight insights on safety and performance data from direct blood glucose measurement technology RUTHERFORD, N.J., June 04, …
Synergy CHC Announces New $20 Million Long-Term Credit Facility
GlobeNewswire
·
June 4, 2025
WESTBROOK, Maine, June 04, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a provider of consumer health care and lifestyle products, announced today that it has entered into a $20 million term loan credit agreement, …
ViaDerma, Inc. Confirms Ongoing Operations and Commitment to Regulatory Compliance
GlobeNewswire
·
June 4, 2025
LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Expert Market: VDRM), a specialty pharmaceutical company, today announced that it remains fully operational and is actively working to complete its overdue annual and quarterly financial …
HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech
GlobeNewswire
·
June 4, 2025
MIRAMAR, Fla., June 04, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by …
FOXO TECHNOLOGIES INC. COMPLETES EQUITY FUNDING AGREEMENT
GlobeNewswire
·
June 4, 2025
WEST PALM BEACH, FLORIDA, June 04, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”) today announced that it has executed an agreement to issue 1,650 of its Series A Cumulative Convertible Redeemable Preferred …
Radiopharm Theranostics Doses First Patient in Phase 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors
GlobeNewswire
·
June 4, 2025
Phase 11 First-In-Human study designed to assess safety, tolerability, right dose for Phase 2 and early signs of efficacy of 177Lu-RAD202 in individuals with advanced HER2-positive solid tumors Previous clinical proof-of concept data2 for targeting HER-2 …
BeautyHealth Surpasses 35,000 Hydrafacial Devices Worldwide Reflecting Growing Consumer Demand for Clinically Proven Skin Health Treatments
GlobeNewswire
·
June 4, 2025
LONG BEACH, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- The BeautyHealth Company (NASDAQ: SKIN), home to flagship brand Hydrafacial™, recently achieved a major milestone with 35,000 Hydrafacial devices installed worldwide, reinforcing its market leadership …
Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology
GlobeNewswire
·
June 4, 2025
CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Journal of the American Society …
Famed Former NFL Safety, Leonard Wheeler, Named Global Ambassador For TULSA-PRO®
GlobeNewswire
·
June 4, 2025
TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation …
Aveanna Healthcare Holdings Completes Acquisition of Thrive Skilled Pediatric Care
GlobeNewswire
·
June 4, 2025
ATLANTA, June 04, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced that it completed its …
The Joint Corp. Appoints Sandi Karrmann as Director
GlobeNewswire
·
June 4, 2025
SCOTTSDALE, Ariz., June 04, 2025 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care through The Joint Chiropractic® network, appointed Sandi Karrmann as a Director to help the company strengthen its core, …
Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis
GlobeNewswire
·
June 4, 2025
SION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that reinforce their potential as either an add-on to standard of care or in a Sionna dual combination Sionna plans to advance SION-719 to a Phase 2a proof-of- …
Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide
GlobeNewswire
·
June 4, 2025
Collaboration is designed to implement a highly scalable clinical pathway for Revita in post GLP-1 weight maintenance, pending FDA approval, potentially benefiting millions of eligible patients Rising interest from patients and payers for an off-ramp from …
Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire
·
June 4, 2025
WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, …
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
GlobeNewswire
·
June 4, 2025
Initial Data from the Ongoing, Blinded Phase 1 Single-Ascending Dose Trial Has Demonstrated Favorable Safety and Pharmacokinetics IND Application Submitted to Expand RESTORE-FA Trial to U.S. Sites; Notice Received from FDA Placing Clinical Hold on IND …
Revive Therapeutics Advances with Next-Generation Bucillamine Development
GlobeNewswire
·
June 4, 2025
TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, is …
Accumulus Synergy und Veeva Systems gehen eine Partnerschaft ein, um die Transformation der Regulierung und die Konnektivität voranzutreiben
GlobeNewswire
·
June 4, 2025
BURLINGAME, Kalifornien, June 04, 2025 (GLOBE NEWSWIRE) -- Accumulus Synergy („Accumulus“) hat heute eine strategische Partnerschaft mit Veeva Systems („Veeva“) bekannt gegeben, deren Schwerpunkt auf der Bereitstellung von Konnektivität liegt, um die Life- …